GMA 105


GLP-1R is a class B GPCR and a major therapeutic target for type 2 diabetes and obesity.  Liraglutide has been approved for obesity, with daily injection. Products with longer half-life are in demand for easier administration and better adherence.


GMA105 is a humanized anti-GLP-1R monoclonal antibody carrying a GLP-1 fragment, potentially to overcome the shortcomings of the existing drug. It could serve as a first long-lasting GLP-1 for obesity, in the hope of having less on-target toxicity.  


GMA105 is currently in phase 2 clinical trials in Australia and New Zealand.